Castle biosciences stock.

Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ...

Castle biosciences stock. Things To Know About Castle biosciences stock.

Europe PMC is an archive of life sciences journal literature. https://orcid.orgDec 1, 2023 · Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: A patent application pending for Castle Biosciences. Kyle R. Covington. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other …Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.

Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: A patent application pending for Castle Biosciences. Kyle R. Covington. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other …According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...

Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.

Castle Biosciences, Inc. Common Stock (CSTL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ... registrant’s common stock on June 30, 2020, as reported by the Nasdaq Global Market. As of March 5, 2021, there were 24,978,424 shares of …Dec 4, 2023 · Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ... Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,820 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …

Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …

The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Ms. Aspinall CSTL stock SEC Form 4 insiders trading. Mara has made over 10 trades of the Castle Biosciences stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 3,825 units of CSTL stock worth $68,774 on 2 June 2023.. The largest trade she's ever made was buying 6,000 units of Castle Biosciences …Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I cutaneous melanoma …Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …

In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded.NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.51 -0.27 (-1.37%) As of 03:38PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Max Full screen …Apr 17, 2023 · In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market... The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...

Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the …

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I cutaneous melanoma …By providing your email address below, you are providing consent to Castle Biosciences to send you the requested Investor Email Alert updates. * Required. Email Address*. Investor Alert Options*. News. Events & Presentations. Quarterly Reports. Annual Reports. SEC Filings.See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Castle Biosciences Inc Registered Shs's market capitalization is $534.59 M by 26.91 M shares outstanding. Castle Biosciences Stock Snapshot 16.00Health has made over 7 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Health sold 250,000 units of CSTL stock worth $8,625,000 on 12 May 2020.Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, …

Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months.

Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...

Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 -4.19% -0.60 Home CSTL •... Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65.0 million in initial consideration to AltheaDx ...Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …Which technical analysis tools can be used to analyze Castle Biosciences, Inc.? Check out various oscillators, moving averages and other technical ...Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 1 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 830 units of CSTL stock worth $17,355 on 10 June 2022.830 units of CSTL stock worth $17,355 on 10 June 2022.Castle Biosciences Inc Registered Shs's market capitalization is $534.59 M by 26.91 M shares outstanding. Castle Biosciences Stock Snapshot 16.00Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business. Ms. Oelschlager CSTL stock SEC Form 4 insiders trading. Kristen has made over 4 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 7,178 units of CSTL stock worth $17,155 on 28 December 2022.. The largest trade she's ever made was selling 10,000 units of Castle …Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.

Castle Biosciences has risen higher in 1 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 25%. Is Castle Biosciences Stock Undervalued? The current Castle Biosciences [ CSTL] share price is $19.99. The Score for CSTL is 73, which is 46% above its historic median score of 50, and infers lower risk ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.Castle Biosciences to Participate in Upcoming Investor Conferences. FRIENDSWOOD, Texas-- (BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle …It’s estimated that there are over 30,000 castles in Ireland. Some are parts of ruins, some are homes, some are offices — and some castles in Ireland are available for people from all over the world to visit and stay in during their vacatio...Instagram:https://instagram. transcendentelectrahomessunoco inc stock1776 quarter valueapple stock forecast 2025 The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86.During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35.The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks. Volume has …View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. what software do financial planners useinvestment banks top Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. FRIENDSWOOD, Texas, November 08, 2023--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major … largest wealth managers Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.